Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.
| Website | http://www.bioxodes.com |
| Revenue | $1 million |
| Employees | 11 (8 on RocketReach) |
| Founded | 2013 |
| Phone | +32 71 23 96 00 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+10 more
(view full list)
|
| Industry | Biotechnology, Manufacturing General, Pharmaceuticals, Manufacturing, Science and Engineering, Drug Discovery, Health Care, Therapeutics |
| Keywords | Inflammatory Diseases, Clinical Stage, Therapeutics, Drug Discovery, Treatment Development, Pharmaceutical Research, Biotechnology, Clinical Trials, Drug Development, Precision Medicine, Thrombosis, Inflammation, Patient Care, Medical Research, Health Solutions, Disease Treatment, Innovative Therapies |
| Competitors | BASF, DuPont, AkzoNobel, Solvay, SABIC, Evonik, Huntsman Corporation, FMC Corporation, Clariant, LANXESS +43 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Bioxodes employee's phone or email?
The Bioxodes annual revenue was $1 million in 2026.
Marc Dechamps is the CEO of Bioxodes.
8 people are employed at Bioxodes.
The NAICS codes for Bioxodes are [3254, 325, 32541, 32].
The SIC codes for Bioxodes are [28, 283].